Intest Res.
2020 Jul;18(3):343-344. 10.5217/ir.2018.00078-c1.
Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
- Affiliations
-
- 1Department of Pharmacy and Kitasato University Kitasato Institute Hospital, Tokyo, Japan
- 2Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
- 3The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan
- KMID: 2504591
- DOI: http://doi.org/10.5217/ir.2018.00078-c1
Figure
-
Fig. 2. (A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.
Fig. 2. (A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
- Comparison of efficacies of once-daily dose multimatrix mesalazine and multiple-dose mesalazine for the maintenance of remission in ulcerative colitis: a randomized, double-blind study
- Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study
- Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
- Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis
